“Efficacy and Safety of Risankizumab Compared with Apremilast in Patients with Moderate Plaque Psoriasis: Mean PASI and BSA Results From the Phase 4 IMMpulse Trial” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s257. doi:10.25251/skin.7.supp.257.